Analyze Your Search


  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Lung Cancer
  Follow Topic   Edit Search
Your search returned 7 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
The New England journal of medicine 
Abstract: Background Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy ... antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of ...
Oncology (4)
Lung Neoplasms (2), Pneumonia (1), more mentions
Lancet (London, England) 
... 0·0001) were significantly higher among participants subsequently diagnosed with lung cancer than among those not diagnosed with cancer... Incident lung cancer (n=129) was significantly less frequent in the 150 mg ... Lung cancer mortality was significantly less common in the canakinumab 300 mg ... the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
Oncology (14), Cardiovascular Diseases (3)
Neoplasms (7), Lung Neoplasms (6), Atherosclerosis (3), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
Abstract: Purpose Patients with squamous non-small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options... ipilimumab or placebo plus paclitaxel and carboplatin in advanced squamous NSCLC... Methods Patients with stage IV or recurrent chemotherapy-naïve squamous NSCLC were randomly assigned (1:1) to receive paclitaxel and carboplatin ...
Oncology (3)
Lung Neoplasms (2), Melanoma (1), more mentions
The New England journal of medicine 
CitationSubset: AIM. CitationSubset: IM. DescriptorName: Algorithms. DescriptorName: Antineoplastic Agents. DescriptorName: Bronchoscopy. DescriptorName: Carcinoma, Non-Small-Cell Lung. DescriptorName: Genes, erbB-1. DescriptorName: Humans. DescriptorName: Immunotherapy. DescriptorName: Lung Neoplasms. DescriptorName: Mutation. DescriptorName: Neoplasm Staging. DescriptorName: Ultrasonography.
Oncology (2)
Lung Neoplasms (2), Carcinoma (1), Neoplasms (1), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
... mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC... and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort... robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC.
Oncology (2)
Lung Neoplasms (2), Neoplasms (2), more mentions
The Journal of clinical investigation 
We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ~50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis. Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers.
Oncology (3)
Neoplasms (2), Fibrosis (2), Pulmonary Fibrosis (1), more mentions
Lung cancer (Amsterdam, Netherlands) 
... to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) with activating EGFR mutations generally involve development of acquired ... We performed a comprehensive survey of 17,319 clinical NSCLC samples (14,170 adenocarcinomas and 3149 NSCLC not otherwise specified (NOS)) and identified 5 cases of FGFR3 ... bypass EGFR blockade by all generations of EGFR TKIs in NSCLC.
Adenocarcinoma (1), Neoplasms (1), more mentions